Gilead's Chronic Hepatitis Delta Infection Treatment Shows Sustained Efficacy, Safety Profile At Two Years
Portfolio Pulse from Vandana Singh
Gilead Sciences announced Week 96 results from the MYR301 Phase 3 clinical trial evaluating bulevirtide for chronic hepatitis delta (HDV) infection. The findings demonstrated improved combined response, sustained virologic response, and a consistent safety profile. Bulevirtide is approved for HDV treatment in Europe but not in the U.S.
June 23, 2023 | 2:38 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Gilead's bulevirtide demonstrated sustained efficacy and safety in treating chronic hepatitis delta infection in Week 96 results of the MYR301 Phase 3 clinical trial.
The Week 96 results of the MYR301 Phase 3 clinical trial showed improved combined response, sustained virologic response, and a consistent safety profile for bulevirtide. This positive data may lead to increased interest in the drug and potential approval in the U.S., which could positively impact Gilead's stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100